date founded
General
About Company
Industry
Sector :
Subsector :
Contacts
Similar Companies440
Accelrys
Accelrys, now known as Biovia, is a subsidiary of Dassault Systèmes that provides scientific enterprise software for bioscience research.
Sector
Subsector
Keywords
Location
Laurus Infosystems
Laurus Infosystems is a software product company that assists in the innovation and manufacturing of pharmaceutical and chemical products.
Sector
Subsector
Keywords
Location
CambridgeSoft
CambridgeSoft provides software solutions to the pharmaceutical, biotechnology, and chemical industries.
Sector
Subsector
Location
total rounds
total raised
ChemAxon
ChemAxon is a leading provider of chemical software development platforms for the biotechnology and pharmaceutical industries.
Sector
Subsector
Keywords
Location
Financials
Co-Investors
People
Founders2
Peter G. Schultz
Pete did his undergraduate and graduate work at the California Institute of Technology. His thesis work with Peter Dervan resulted in the first synthetic molecules (polypyrroleamides) that sequence-selectively cleave DNA. In 1985, after postdoctoral studies at the Massachusetts Institute of Technology with Chris Walsh, he joined the faculty of the University of California at Berkeley, where he was Professor of Chemistry, Principal Investigator at Lawrence Berkeley National Laboratory and an Investigator of the Howard Hughes Medical Institute. Schultz joined the faculty of Scripps in 1999 where he is currently the Scripps Professor of Chemistry. He founded and was the Institute Director of the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, CA from 1999 to 2010. In addition, Pete is a founder of Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Ilypsa, Ambrx, and Wildcat Technologies, pioneers in the application of diversity based approaches to problems in chemistry, materials science and medicine. His awards include the Waterman Award of the National Science Foundation, membership in the National Academy of Sciences and National Institute of Medicine, the 1994 Wolf Prize in Chemistry, the 2003 Paul Ehrlich Prize, and the 2005 Arthur C. Cope Award of the American Chemical Society. - See more at: http://www.ardelyx.com/board-of-directors/peter-g-schultz-ph-d/#sthash.Xqr2TE1b.dpuf
current job
organization founded
Peter G. Schultz
Alejandro Zaffaroni
Alejandro Zaffaroni (1923-2014) founded many companies, including Alexza Pharmaceuticals. A native of Montevideo, Uruguay, Dr. Zaffaroni received his B.Sc. from the University of Montevideo in 1941, and his PhD in biochemistry from the University of Rochester in 1949. In 1951 Dr. Zaffaroni joined Syntex Corporation, a small chemical company in Mexico, which was prominent in steroid research. He subsequently played a key role in transforming it into a major pharmaceutical company headquartered in the United States that pioneered the development of the birth control pill. This was the beginning of Dr. Zaffaroni’s extraordinary career in scientific and business entrepreneurship. Eventually he became President of Syntex Laboratories and President of Syntex Research Institute. In 1968, he resigned from Syntex to establish ALZA Corporation to pursue the concept of improving medical treatment through controlled drug delivery. ALZA Corporation was acquired by Johnson & Johnson in 2001. In 1980, Dr. Zaffaroni founded DNAX Ltd. a company that develops macromolecular products for medicine by combining the technologies of genetic engineering and immunobiology. DNAX Research Institute of Molecular and Cellular Biology Inc. was acquired by Schering-Plough in 1982. Another creative concept became a reality in 1988, when Dr. Zaffaroni founded Affymax, the company that pioneered the development of combinatorial chemistry which dramatically reduced the cost and time to identify promising medicines. The technology developed by Affymax combines synthetic chemistry with advanced techniques pioneered by the semiconductor industry, notably photolithography, miniaturization and parallel processing. Affymax was acquired by Glaxo plc in 1995. In 1991, Dr. Zaffaroni founded Affymetrix, an acknowledged leader in developing "gene chips", an exciting new scientific and technical arena that holds the potential to revolutionize human genetics, providing an ongoing foundation for understanding, diagnosing and treating human disease. In 1994 Dr. Zaffaroni co-founded Symyx, the combinatorial chemistry company dedicated to the discovery of materials such as superconductors, magnets, catalysts and polymers. The technologies developed at Symyx made it possible to synthesize and analyze up to 100,000 materials in one experiment; thus, dramatically reducing the time and cost of identifying promising compounds for use in electronic, semiconductor and chemical application. Symyx was acquired by Accelrys in 2010. In 1997, Dr. Zaffaroni founded Maxygen, Inc. The mission of Maxygen, Inc. was to develop broad technologies which improve the function of a protein or polynucleotide through the evolution of its DNA sequence, a process termed molecular breeding. In 2000, Dr. Zaffaroni founded Alexza, with the vision of treating acute and intermittent diseases with a new and novel technology concept, which became the Staccato® technology The success of the companies Dr. Zaffaroni founded attest to the clarity of his vision and the practicality of his ideas for improving therapy. He endeavored to provide a new dimension for individual health and the treatment of illness in the world. In all his activities, his deepest personal satisfaction came from finding new ways to apply the findings of science to the treatment of disease and the prevention of human suffering. Among his many honors, in 1995 Dr. Zaffaroni was awarded the National Medal of Technology by President Clinton in recognition of his contributions to the pharmaceutical and biotechnology industries. This Medal is the highest award that the United States bestows for individual achievement in science and technology. Alexza is truly fortunate to have had Dr. Zaffaroni as its founder. He was not only an inspiration, he was also a friend, and he is sorely missed by all of us at Alexza.
current job
count Of Investments
count Of Exists
Alejandro Zaffaroni
Employee Profiles207
Eddy Vande Water
BIOVIA R&D Software Architect Director
Matthew Caputo
Senior program manager, professional services
Bryan Billings
Technical customer support senior manager
Laura Venekamp
Training and enablement manager biovia